An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals reported a record comprehensive income of A$166 million for 2024, driven by strong sales and royalties from its product DAYBUE™. The company is poised for further growth with the approval of DAYBUE™ in Canada and ongoing regulatory processes in Europe and Japan. Neuren’s financial success is further supported by its strategic partnership with Acadia Pharmaceuticals, which contributed significantly to its income through royalties and milestone payments. The company is also advancing its NNZ-2591 product, which has shown promising Phase 2 trial results, positioning Neuren for continued expansion in the neurodevelopmental disorder treatment market.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on developing therapies for neurodevelopmental disorders. Its primary products include DAYBUE™ (trofinetide), which has been approved in the US and Canada, and NNZ-2591, which is in development for multiple syndromes. The company is expanding its market reach with applications in Europe and Japan.
YTD Price Performance: 10.82%
Average Trading Volume: 588
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.07B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.